Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution

Yang, Pei; Wang, Yongzhi; Peng, Xiaoxia; You, Guoxiang; Zhang, Wei; Yan, Wei; Bao, Zhaoshi; Wang, Yinyan; Qiu, Xiaoguang; Jiang, Tao

doi:10.1007/s11060-013-1103-9

Cited by 131 publications

(92 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma (83,84), endometrial cancer (85), and prostate cancer (86), and reduced expression is found in numerous other tumor types such as lung (87) and breast cancer (88).…”

Section: Phosphatase and Tensin Homolog (Pten)mentioning

confidence: 99%

FTY720 for cancer therapy (Review)

Zhang

Wang

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

Abstract. 2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. As an immunosuppressant, it displays its anti-multiple sclerosis, immunosuppressive effects by activating sphingosine-1-phosphate receptors (S1PRs). In addition to the immunosuppressive effects, FTY720 also shows preclinical antitumor efficacy in several cancer models. In most cases, phosphorylation of FTY720 is not required for its cytotoxic effect, indicating the involvement of S1PR-independent mechanisms which are starkly different from the immunosuppressive property of FTY720. In the present study, we reviewed the rapidly advancing field of FTY720 in cancer therapy as well as some molecular targets of the unphosphorylated form of FTY720.

show abstract

Section: Phosphatase and Tensin Homolog (Pten)mentioning

confidence: 99%

FTY720 for cancer therapy (Review)

Zhang

Wang

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Even using multiple modalities of treatment, including maximal safe resection, radiotherapy, and chemotherapy, the prognosis of patients with malignant gliomas remains dismal (1,2). Therefore, novel therapeutic strategies and drugs for treatment of malignant gliomas are urgently required.…”

Section: Introductionmentioning

confidence: 99%

Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways

Wang¹,

Dai

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Resveratrol (Res), a natural polyphenolic compound, has anticancer activity in a variety of cancers. In the present study, the antitumor effect and underlying molecular mechanism of Res on rat C6 glioma growth was studied. The results demonstrated that Res inhibited glioma cell proliferation, arrested cell cycle in S phase and induced apoptosis in vitro. Res also suppressed intracranial C6 tumor growth in vivo and prolonged survival in a fraction of the rats bearing intracranial gliomas. Res significantltly downregulated the specific miRs, including miR-21, miR-30a-5p and miR-19, which have been identified as oncomiRs in our previous studies, and altered the expression of their targeting and crucial genes for glioma formation and progression such as p53, PTEN, EGFR, STAT3, COX-2, NF-κB and PI3K/AKT/mTOR pathway. Therefore, the anti-glioma effect of Res, at least in part, is through the regulation of oncogenic miRNAs. The effect of Res on noncoding RNAs should be studied further. Res is a potential multi-targeting drug for the treatment of gliomas. IntroductionMalignant gliomas are the most common and highly aggressive primary brain tumors. Even using multiple modalities of treatment, including maximal safe resection, radiotherapy, and chemotherapy, the prognosis of patients with malignant gliomas remains dismal (1,2). Therefore, novel therapeutic strategies and drugs for treatment of malignant gliomas are urgently required.A large number of chemopreventive and chemotherapeutic agents have been discovered from natural products and provided promising approaches to treat and prevent cancer (3,4). Res (3,5,4'-trihydroxy-trans-stilbene), a naturally polyphenolic compound, has been identified in the skin of red grapes, peanuts and various food products. It has a variety of important biological effects such as suppression of platelet aggregation, anti-inflammatory, anti-oxidant, and vasorelaxant activities (5-7). Res also exhibits antitumor properties by blocking the three stages of carcinogenesis, initiation, promotion and progression (8). Res has exerted anticancer effects against prostate, breast, leukemia and other epithelial cancer cells. There are some reports on the studies of the treatment of gliomas with Res (9-12) but the molecular mechanism of its antitumorigenic or chemopreventive activities is complex and not fully understood.The objective of the present study was to investigate the anti-proliferative effect of Res on glioma cells using both in vitro and in vivo models. It is well known that small non-coding regulatory RNAs -microRNAs (miRs) are found to be dysregulated in almost all types of cancers and play important roles in cancer development and progression (13)(14)(15)(16)(17). Recent studies have demonstrated that miRs can be regulated by natural agents such as curcumin and Res resulting in suppression of tumor growth, drug resistance and metastasis (18-21). Our previous studies have confirmed that specific miRs, including miR-21, miR19 and miR-30a-5p are upregulated in GBMs with significa...

show abstract

“…8,13 Associations have been made that link tumor location and genetic features in glioma. For example, anatomic characteristics have been demonstrated for several tumor-related molecular bio-markers, such as 1p and/or 19q, 14 isocitrate dehydrogenase 1,15 O6-methylguanine DNA methyltransferase (MGMT), 16 and…”

mentioning

confidence: 99%

Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis

Wang

Zhang²,

et al. 2014

American Journal of Neuroradiology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Brain tumor location has proved to be a prognostic factor that may be associated with features of neoplastic origin. Mutation of p53 is an atypical genetic change that occurs during tumorigenesis. Thus, a potential correlation may exist between tumor location and p53 status. The purpose of the current study was to identify anatomic characteristics of mutant p53 expression by using quantitative neuroimaging analyses.

show abstract

Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution

Cited by 131 publications

References 42 publications

FTY720 for cancer therapy (Review)

FTY720 for cancer therapy (Review)

Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways

Mapping p53 Mutations in Low-Grade Glioma: A Voxel-Based Neuroimaging Analysis

Contact Info

Product

Resources

About